No Data
TD Cowen Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $554
Truist Financial Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: ARS Pharmaceuticals (SPRY), BillionToOne, Inc. Class A (BLLN) and Praxis Precision Medicines (PRAX)
Xenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly Seizures
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)